Business
Beam Therapeutics Announces Upcoming Preclinical Data Presentations at the American Society of Hematology Annual Meeting
Preclinical Data Demonstrates that BEAM-102 Makassar Base Editing Converts Sickle Hemoglobin to Functional Hemoglobin for Potential Treatment of Sickle Cell
About this update from Beam Therapeutics Inc.
[{"type":"text","content":"Preclinical Data Demonstrates that BEAM-102 Makassar Base Editing Converts Sickle Hemoglobin to Functional Hemoglobin for Potential Treatment of Sickle Cell Disease New In Vivo Data Highlight Novel LNP Screening Technology to Identify LNPs for Delivery of Base Editors to Tissues Beyond the Liver, Including to Blood Stem Cells CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that preclinical data highlighting the company’s Makassar base editing approach for the potential treatment of sickle cell disease (SCD) and its proprietary lipid nanoparticle (LNP) screening capabilities will be presented during two poster sessions at the 63rd American Society of Hematology (ASH) Annual Meeting. In addition, Beam will present an overview on the application of base editing for the treatment of beta-hemoglobinopathies and other genetic blood disorders during a Scientific Program session titled, “Gene Editing 2.0: Advances in Gene Editing to Treat Genetic Blood Disorders.” The ASH Annual Meeting is being held December 11-14, 2021, virtually and in Atlanta. “We look forward to presenting these new data at ASH, which further support our leadership position in the field of base editing and the significant opportunity we have to potentially make a difference for patients in need of meaningful treatment options,” said Giuseppe Ciaramella, Ph.D., president and chief scientific officer of Beam. “The additional preclinical data being presented from our Makassar program continue to validate the potential of our base editing approach to treating SCD, which is designed to correct sickle globin to a normally functioning hemoglobin variant. In addition, the ability of our in vivo high-throughput LNP screening technology to identify novel LNPs capable of delivering our editors to stem cells is exciting and supports a promising delivery platform that could eventually eliminate the need for transplant in sickle cell disease and other genetic blood disorders. Taken together, these data, coupled with our ongoing work around non-genotoxic conditioning, give us hope to be able to provide a more holistic treatment approach for patients with SCD and beyond.” Details of the poster presentations are as follows: Poster Title: Co...